CSL Announces New Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Ethan Settembre, PhD, Vice President, Research, CSL R&D Seqirus Vaccines Innovation Unit and study author, discusses key findings from the data published in Molecular Therapy – Methods and Clinical Development and the company’s next sa-mRNA technology platform.

Ethan Settembre, PhD, Vice President, Research, CSL R&D Seqirus Vaccines Innovation Unit, one of the world’s largest influenza vaccine producers. At CSL Seqirus, Ethan leads the R&D team responsible for developing vaccines that offer the greatest protection possible against infectious diseases, with a specific focus on influenza, by both improving current approaches and pursuing new vaccine technologies. These new innovations include approaches to RNA vaccines, cell-based manufacturing methods, adjuvants, and protein-based antigens.

Ethan received post-doctoral training in Structural Vaccinology at Harvard Medical School, where he helped elucidate the structure of key viral proteins at the atomic level. Previously, Ethan worked at Novartis Vaccines and Diagnostics where he led projects in multiple disease areas (e.g. RSV, Influenza, Parvovirus B19, etc.).